CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy
| Status: | Recruiting |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/9/2018 |
| Start Date: | January 2016 |
| End Date: | May 2019 |
| Contact: | Amanda Simmons |
| Email: | amandals@stanford.edu |
| Phone: | 650-724-4606 |
A Pilot Study of Perfusion CT for Lung Tumors Treated With Stereotactic Ablative Radiation Therapy (SABR)
This pilot clinical trial studies computed tomography (CT) perfusion imaging in predicting
treatment response in patients with non-small cell lung cancer or tumors that have spread
from the primary site (place where it started) to the lungs (metastases) treated with
stereotactic ablative radiation therapy. CT perfusion imaging is a special type of CT that
uses an injected dye in order to see how blood flow through tissues, including lung tissue.
CT perfusion imaging of the lungs may help doctors learn whether perfusion characteristics of
lung tumors may be predictive of response to treatment and whether lung perfusion
characteristics can be used to follow response to treatment.
treatment response in patients with non-small cell lung cancer or tumors that have spread
from the primary site (place where it started) to the lungs (metastases) treated with
stereotactic ablative radiation therapy. CT perfusion imaging is a special type of CT that
uses an injected dye in order to see how blood flow through tissues, including lung tissue.
CT perfusion imaging of the lungs may help doctors learn whether perfusion characteristics of
lung tumors may be predictive of response to treatment and whether lung perfusion
characteristics can be used to follow response to treatment.
PRIMARY OBJECTIVES:
I. To assess the feasibility of performing perfusion CT imaging (CT perfusion imaging) at
baseline, within 48 hours post-stereotactic ablative radiation therapy (SABR), and at 2-4
months SABR in patients undergoing SABR for treatment of a lung tumor per standard of care.
SECONDARY OBJECTIVES:
I. To determine the range (variability) of perfusion parameters, including blood flow, blood
volume, transit time, and permeability at each time point.
II. To assess the change in perfusion parameters between these time points. III. To correlate
any change in perfusion parameters with circulating-tumor deoxyribonucleic acid (DNA) levels
at these time points.
IV. To correlate perfusion parameters with tumor response 1 year post-SABR.
OUTLINE:
Patients undergo CT perfusion imaging of the lungs at baseline, within 48 hours of first
SABR, and at 2-4 months after completion of SABR.
After completion of treatment, patients are followed up at 2-4 months and then at 1 year.
I. To assess the feasibility of performing perfusion CT imaging (CT perfusion imaging) at
baseline, within 48 hours post-stereotactic ablative radiation therapy (SABR), and at 2-4
months SABR in patients undergoing SABR for treatment of a lung tumor per standard of care.
SECONDARY OBJECTIVES:
I. To determine the range (variability) of perfusion parameters, including blood flow, blood
volume, transit time, and permeability at each time point.
II. To assess the change in perfusion parameters between these time points. III. To correlate
any change in perfusion parameters with circulating-tumor deoxyribonucleic acid (DNA) levels
at these time points.
IV. To correlate perfusion parameters with tumor response 1 year post-SABR.
OUTLINE:
Patients undergo CT perfusion imaging of the lungs at baseline, within 48 hours of first
SABR, and at 2-4 months after completion of SABR.
After completion of treatment, patients are followed up at 2-4 months and then at 1 year.
Inclusion Criteria:
- Patients undergoing SABR for the treatment of a lung tumor, inclusive of non-small
cell lung cancer or lung metastases
Exclusion Criteria:
- Patients who are pregnant or are trying to become pregnant are excluded from this
study
- Patients with renal failure, defined as glomerular filtration rate (GFR) < 60 at the
time of the radiation treatment-planning (RTP) scan, will be excluded
We found this trial at
1
site
Palo Alto, California 94304
Principal Investigator: Maximilian Diehn
Phone: 650-724-4606
Click here to add this to my saved trials
